| Project/Area Number |
15K09456
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
ISHIDA Tadao 札幌医科大学, 医学部, 研究員 (20305220)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
池田 博 札幌医科大学, 医学部, 助教 (60570132)
丸山 玲緒 札幌医科大学, 医学部, 研究員 (60607985)
石黒 一也 札幌医科大学, 医学部, 研究員 (90784439)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 多発性骨髄腫 / エピジェネティクス / ヒストンメチル化 / メチル化 / エピジェネッティック / ゲノム |
|---|
| Outline of Final Research Achievements |
DNA methylations and histone modifications are deeply involved in oncogenesis and inhibitors which target epigenetic modifications are used for cancer therapies. In this study, we aimed to clarify the histone methylation inhibitors which suppressed the survival of multiple myeloma (MM). As a result, we found that DOT1L inhibitors strongly repressed the proliferation of MM. Our results suggest DOT1L could be a therapeutic target in MM.
|
